世界の発作性夜間ヘモグロビン尿症治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4443
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、94ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、発作性夜間ヘモグロビン尿症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ACH-4471、ALN-CC5、ALXN-1210、AMY-101、APL-2、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・発作性夜間ヘモグロビン尿症治療の市場動向
・企業の競争状況、市場シェア
・発作性夜間ヘモグロビン尿症治療の種類別市場規模（ACH-4471、ALN-CC5、ALXN-1210、AMY-101、APL-2、その他）
・発作性夜間ヘモグロビン尿症治療の用途別市場規模（病院、診療所、その他）
・発作性夜間ヘモグロビン尿症治療の北米市場規模2016-2027（アメリカ、カナダ）
・発作性夜間ヘモグロビン尿症治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・発作性夜間ヘモグロビン尿症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・発作性夜間ヘモグロビン尿症治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・発作性夜間ヘモグロビン尿症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Achillion Pharmaceuticals Inc、Akari Therapeutics Plc、Alexion Pharmaceuticals Inc、Alnylam Pharmaceuticals Inc、Amgen Inc、Apellis Pharmaceuticals Inc、F. Hoffmann-La Roche Ltd、ISU ABXIS Co Ltd、Novartis AG、NovelMed Therapeutics Inc、Omeros Corp、Ra Pharmaceuticals Inc、Regeneron Pharmaceuticals Inc、Regenesance BV）
・結論

Market Analysis and Insights: Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market
The global Paroxysmal Nocturnal Hemoglobinuria Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Paroxysmal Nocturnal Hemoglobinuria Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Paroxysmal Nocturnal Hemoglobinuria Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Paroxysmal Nocturnal Hemoglobinuria Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Paroxysmal Nocturnal Hemoglobinuria Treatment market.

Global Paroxysmal Nocturnal Hemoglobinuria Treatment Scope and Market Size
Paroxysmal Nocturnal Hemoglobinuria Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Paroxysmal Nocturnal Hemoglobinuria Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
ACH-4471
ALN-CC5
ALXN-1210
AMY-101
APL-2
Others

Segment by Application
Hospital
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Apellis Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
ISU ABXIS Co Ltd
Novartis AG
Alnylam Pharmaceuticals Inc
Amgen Inc
Ra Pharmaceuticals Inc

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 ACH-4471
1.2.3 ALN-CC5
1.2.4 ALXN-1210
1.2.5 AMY-101
1.2.6 APL-2
1.2.7 Others
1.3 Market by Application
1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Perspective (2016-2027)
2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Growth Trends by Regions
2.2.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Industry Dynamic
2.3.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Trends
2.3.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers
2.3.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
2.3.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue
3.1.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue (2016-2021)
3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue
3.4 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio
3.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2020
3.5 Paroxysmal Nocturnal Hemoglobinuria Treatment Key Players Head office and Area Served
3.6 Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Product Solution and Service
3.7 Date of Enter into Paroxysmal Nocturnal Hemoglobinuria Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Type
4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Type (2016-2021)
4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Type (2022-2027)

5 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Application
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Application (2016-2021)
5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2016-2027)
6.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type
6.2.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2021)
6.2.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2022-2027)
6.2.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2027)
6.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application
6.3.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2021)
6.3.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2022-2027)
6.3.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2027)
6.4 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country
6.4.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2016-2021)
6.4.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2016-2027)
7.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type
7.2.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2021)
7.2.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2022-2027)
7.2.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2027)
7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application
7.3.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2021)
7.3.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2022-2027)
7.3.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2027)
7.4 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country
7.4.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2016-2021)
7.4.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2016-2027)
8.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type
8.2.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application
8.3.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region
8.4.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2016-2027)
9.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type
9.2.1 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2027)
9.3 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application
9.3.1 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2027)
9.4 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country
9.4.1 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2016-2027)
10.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type
10.2.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application
10.3.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country
10.4.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Achillion Pharmaceuticals Inc
11.1.1 Achillion Pharmaceuticals Inc Company Details
11.1.2 Achillion Pharmaceuticals Inc Business Overview
11.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.1.4 Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.1.5 Achillion Pharmaceuticals Inc Recent Development
11.2 Akari Therapeutics Plc
11.2.1 Akari Therapeutics Plc Company Details
11.2.2 Akari Therapeutics Plc Business Overview
11.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.2.4 Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.2.5 Akari Therapeutics Plc Recent Development
11.3 Alexion Pharmaceuticals Inc
11.3.1 Alexion Pharmaceuticals Inc Company Details
11.3.2 Alexion Pharmaceuticals Inc Business Overview
11.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.3.4 Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.3.5 Alexion Pharmaceuticals Inc Recent Development
11.4 Alnylam Pharmaceuticals Inc
11.4.1 Alnylam Pharmaceuticals Inc Company Details
11.4.2 Alnylam Pharmaceuticals Inc Business Overview
11.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.4.4 Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.4.5 Alnylam Pharmaceuticals Inc Recent Development
11.5 Amgen Inc
11.5.1 Amgen Inc Company Details
11.5.2 Amgen Inc Business Overview
11.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.5.4 Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.5.5 Amgen Inc Recent Development
11.6 Apellis Pharmaceuticals Inc
11.6.1 Apellis Pharmaceuticals Inc Company Details
11.6.2 Apellis Pharmaceuticals Inc Business Overview
11.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.6.4 Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.6.5 Apellis Pharmaceuticals Inc Recent Development
11.7 F. Hoffmann-La Roche Ltd
11.7.1 F. Hoffmann-La Roche Ltd Company Details
11.7.2 F. Hoffmann-La Roche Ltd Business Overview
11.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.7.4 F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.7.5 F. Hoffmann-La Roche Ltd Recent Development
11.8 ISU ABXIS Co Ltd
11.8.1 ISU ABXIS Co Ltd Company Details
11.8.2 ISU ABXIS Co Ltd Business Overview
11.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.8.4 ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.8.5 ISU ABXIS Co Ltd Recent Development
11.9 Novartis AG
11.9.1 Novartis AG Company Details
11.9.2 Novartis AG Business Overview
11.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.9.4 Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.9.5 Novartis AG Recent Development
11.10 NovelMed Therapeutics Inc
11.10.1 NovelMed Therapeutics Inc Company Details
11.10.2 NovelMed Therapeutics Inc Business Overview
11.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.10.4 NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.10.5 NovelMed Therapeutics Inc Recent Development
11.11 Omeros Corp
11.11.1 Omeros Corp Company Details
11.11.2 Omeros Corp Business Overview
11.11.3 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.11.4 Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.11.5 Omeros Corp Recent Development
11.12 Ra Pharmaceuticals Inc
11.12.1 Ra Pharmaceuticals Inc Company Details
11.12.2 Ra Pharmaceuticals Inc Business Overview
11.12.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.12.4 Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.12.5 Ra Pharmaceuticals Inc Recent Development
11.13 Regeneron Pharmaceuticals Inc
11.13.1 Regeneron Pharmaceuticals Inc Company Details
11.13.2 Regeneron Pharmaceuticals Inc Business Overview
11.13.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.13.4 Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.13.5 Regeneron Pharmaceuticals Inc Recent Development
11.14 Regenesance BV
11.14.1 Regenesance BV Company Details
11.14.2 Regenesance BV Business Overview
11.14.3 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.14.4 Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
11.14.5 Regenesance BV Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of ACH-4471
Table 3. Key Players of ALN-CC5
Table 4. Key Players of ALXN-1210
Table 5. Key Players of AMY-101
Table 6. Key Players of APL-2
Table 7. Key Players of Others
Table 8. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Regions (2016-2021)
Table 12. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Regions (2022-2027)
Table 14. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Trends
Table 15. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers
Table 16. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
Table 17. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints
Table 18. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Players (2016-2021)
Table 20. Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2020)
Table 21. Ranking of Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Product Solution and Service
Table 25. Date of Enter into Paroxysmal Nocturnal Hemoglobinuria Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type (2016-2021)
Table 29. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Application (2016-2021)
Table 33. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 65. Achillion Pharmaceuticals Inc Company Details
Table 66. Achillion Pharmaceuticals Inc Business Overview
Table 67. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 68. Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 69. Achillion Pharmaceuticals Inc Recent Development
Table 70. Akari Therapeutics Plc Company Details
Table 71. Akari Therapeutics Plc Business Overview
Table 72. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 73. Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 74. Akari Therapeutics Plc Recent Development
Table 75. Alexion Pharmaceuticals Inc Company Details
Table 76. Alexion Pharmaceuticals Inc Business Overview
Table 77. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 78. Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 79. Alexion Pharmaceuticals Inc Recent Development
Table 80. Alnylam Pharmaceuticals Inc Company Details
Table 81. Alnylam Pharmaceuticals Inc Business Overview
Table 82. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 83. Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 84. Alnylam Pharmaceuticals Inc Recent Development
Table 85. Amgen Inc Company Details
Table 86. Amgen Inc Business Overview
Table 87. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 88. Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 89. Amgen Inc Recent Development
Table 90. Apellis Pharmaceuticals Inc Company Details
Table 91. Apellis Pharmaceuticals Inc Business Overview
Table 92. Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 93. Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 94. Apellis Pharmaceuticals Inc Recent Development
Table 95. F. Hoffmann-La Roche Ltd Company Details
Table 96. F. Hoffmann-La Roche Ltd Business Overview
Table 97. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 98. F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 99. F. Hoffmann-La Roche Ltd Recent Development
Table 100. ISU ABXIS Co Ltd Company Details
Table 101. ISU ABXIS Co Ltd Business Overview
Table 102. ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 103. ISU ABXIS Co Ltd Recent Development
Table 104. Novartis AG Company Details
Table 105. Novartis AG Business Overview
Table 106. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 107. Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 108. Novartis AG Recent Development
Table 109. NovelMed Therapeutics Inc Company Details
Table 110. NovelMed Therapeutics Inc Business Overview
Table 111. NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 112. NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 113. NovelMed Therapeutics Inc Recent Development
Table 114. Omeros Corp Company Details
Table 115. Omeros Corp Business Overview
Table 116. Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 117. Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 118. Omeros Corp Recent Development
Table 119. Ra Pharmaceuticals Inc Company Details
Table 120. Ra Pharmaceuticals Inc Business Overview
Table 121. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 122. Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 123. Ra Pharmaceuticals Inc Recent Development
Table 124. Regeneron Pharmaceuticals Inc Company Details
Table 125. Regeneron Pharmaceuticals Inc Business Overview
Table 126. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 127. Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 128. Regeneron Pharmaceuticals Inc Recent Development
Table 129. Regenesance BV Company Details
Table 130. Regenesance BV Business Overview
Table 131. Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Product
Table 132. Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021) & (US$ Million)
Table 133. Regenesance BV Recent Development
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type: 2020 VS 2027
Figure 2. ACH-4471 Features
Figure 3. ALN-CC5 Features
Figure 4. ALXN-1210 Features
Figure 5. AMY-101 Features
Figure 6. APL-2 Features
Figure 7. Others Features
Figure 8. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application: 2020 VS 2027
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Paroxysmal Nocturnal Hemoglobinuria Treatment Report Years Considered
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Regions: 2020 VS 2027
Figure 16. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Regions (2022-2027)
Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Players in 2020
Figure 18. Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2020
Figure 20. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type (2016-2021)
Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type (2022-2027)
Figure 22. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2016-2027)
Figure 24. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2016-2027)
Figure 25. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2016-2027)
Figure 26. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2016-2027)
Figure 30. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2016-2027)
Figure 31. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2016-2027)
Figure 32. Germany Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region (2016-2027)
Figure 42. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2016-2027)
Figure 50. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2016-2027)
Figure 51. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2016-2027)
Figure 52. Mexico Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2016-2027)
Figure 58. Turkey Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Achillion Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 62. Akari Therapeutics Plc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 63. Alexion Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 64. Alnylam Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 65. Amgen Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 66. Apellis Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 67. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 68. ISU ABXIS Co Ltd Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 69. Novartis AG Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 70. NovelMed Therapeutics Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 71. Omeros Corp Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 72. Ra Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 73. Regeneron Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 74. Regenesance BV Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed

Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4443 2021年4月 94Pages
QYResearch社発行の本調査資料では、発作性夜間ヘモグロビン尿症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ACH-4471、ALN-CC5、ALXN-1210、AMY-101、APL-2、その他）、用途別市場規模（病院、診療所、...

世界の夜行性多尿症治療市場規模・現状・予測（2021年-2027年）

Global Nocturnal Polyuria Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4151 2021年4月 92Pages
QYResearch社発行の本調査資料では、夜行性多尿症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（鎮痙薬、デスモプレシン、抗コリン薬、その他）、用途別市場規模（病院薬局、オンライン薬局、ドラッグストア、その他）、主要地域別市場規模（北...

世界の発作性上室性頻拍市場規模・現状・予測（2021年-2027年）

Global Paroxysmal Supraventricular Tachycardia Market Size, Status and Forecast 2021-2027
QYR2104Z4444 2021年4月 93Pages
QYResearch社発行の本調査資料では、発作性上室性頻拍のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（EPS、心エコー検査、ホルターモニター、その他）、用途別市場規模（病院、専門クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨ...

世界の脂質障害治療市場規模・現状・予測（2021年-2027年）

Global Lipid Disorder Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3432 2021年4月 98Pages
QYResearch社発行の本調査資料では、脂質障害治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アトルバスタチン、フルバスタチン、ロスバスタチン、シンバスタチン、プラバスタチン、その他）、用途別市場規模（病院、クリニック、その他）、主要...

世界のジフテリア治療市場規模・現状・予測（2021年-2027年）

Global Diphtheria Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z1902 2021年4月 95Pages
QYResearch社発行の本調査資料では、ジフテリア治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（破傷風免疫グロブリン、破傷風トキソイド、破傷風-ジフテリア、ジフテリアトキソイド、百日咳）、用途別市場規模（抗毒素、抗生物質、その他）、主...

世界のナルコレプシー治療市場規模・現状・予測（2021年-2027年）

Global Narcolepsy Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4022 2021年4月 94Pages
QYResearch社発行の本調査資料では、ナルコレプシー治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（オキシベートナトリウム、抗うつ薬、中枢神経刺激薬、その他）、用途別市場規模（脱力発作を伴う原発性ナルコレプシー、脱力発作を伴わない原発...

世界の水疱性類天疱瘡治療市場規模・現状・予測（2021年-2027年）

Global Bullous Pemphigoid Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z1030 2021年4月 97Pages
QYResearch社発行の本調査資料では、水疱性類天疱瘡治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（免疫抑制薬、ステロイド、抗生物質・防腐剤、鎮痛薬）、用途別市場規模（病院薬局、小売薬局、通信販売薬局）、主要地域別市場規模（北米、アメ...

世界の裂肛治療市場規模・現状・予測（2021年-2027年）

Global Anal Fissure Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0309 2021年4月 91Pages
QYResearch社発行の本調査資料では、裂肛治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（局所ニトログリセリン、カルシウムチャネル遮断薬、便軟化剤、その他）、用途別市場規模（クリニック、病院、その他）、主要地域別市場規模（北米、アメリ...

世界の軟骨肉腫治療市場規模・現状・予測（2021年-2027年）

Global Chondrosarcoma Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z1305 2021年4月 99Pages
QYResearch社発行の本調査資料では、軟骨肉腫治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（外科的治療、化学療法、放射線療法）、用途別市場規模（病院、専門クリニック、がん治療センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ...

世界の多発性内分泌腺腫症治療市場規模・現状・予測（2021年-2027年）

Global Multiple Endocrine Neoplasia Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3952 2021年4月 97Pages
QYResearch社発行の本調査資料では、多発性内分泌腺腫症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬物治療、外科治療）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中...

世界の発作性夜間ヘモグロビン尿症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market The global Paroxysmal Nocturnal Hemoglobinuria Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy…
世界の夜行性多尿症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Nocturnal Polyuria Treatment Market The global Nocturnal Polyuria Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integri…
世界の発作性上室性頻拍市場規模・現状・予測（2021年-2027年） Paroxysmal supraventricular tachycardia (PSVT) is a type of supraventricular tachycardia. Often people have no symptoms. Otherwise symptoms may include palpitations, feeling lightheaded, sweating, shortness of breath, and chest pain. Episodes start and end suddenly. About 2.3 per 1000 people have pa…
世界の網膜芽細胞腫治療市場規模・現状・予測（2021年-2027年） Retinoblastoma is a cancer that starts in the retina, the very back part of the eye. Market Analysis and Insights: Global Retinoblastoma Treatment Market The global Retinoblastoma Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during…
世界の光線療法治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Phototherapy Treatment Market The global Phototherapy Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the repo…